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Patterns of Neoplasia in c-Mos Transgenic Mice and Their Relevance 
to Multiple Endocrine Neoplasia 
Nicholas Schulz,* Friedrich Propst,^  Michael M. Rosenberg,* R. Ilona Linnoila,^  Richard 
S. Paules,* Douglas Schulte,* and George F. Vande Woude* 
We have previously described a neurological phenotype for transgenic mice carrying the c-Mos 
proto-oncogene. Pheochromocytomas and C-cell thyroid neoplasms occur in these transgenic lines in 
patterns that are simitar to those seen in multiple endocrine neoplasia type 2 (MEN 2). Charac-
terization of the pathological lesions via immunohistochemistry underscores similarities between 
MEN 2 and these transgenic mice. When transgenic mice that do not display the MEN 2 phenotype are 
crossed to a different background, the progeny display the MEN 2 phenotype. Thus the interaction of 
the background with the transgene is such that it can suppress tumor information. This observation 
bears special relevance to the human syndrome in that this model system may be used to study the 
question of penetrance of phenotype. (Henry Ford Hosp Med J 1992;40:307-11) 
The role of oncogenes in the mechanism of carcinogenesis has been explored through the use of transgenic animals 
(1). In these systems the site of tumor formation is usually di-
rected by the promoter sequence used to express the oncogene. 
For example, when a mouse mammary tumor viras promoter is 
linked to the c-myc oncogene, an increased incidence of mam-
mary tumors is observed in stochastic fashion (2). In contrast, 
when an IgG enhancer is used with c-myc, lymphoid neoplasms 
develop (3). An insulin promoter linked to the SV40 large T an-
tigen produces pancreatic p cell tumors (4). Thus far, however, 
these model systems have not yielded a pattern of tumors resem-
bling that seen in familial neoplasia syndromes such as multiple 
endocrine neoplasia type 2 (MEN 2). 
Transgenic mice carrying a constitutively activated mos 
proto-oncogene display neurological phenotypes manifested by 
behavioral abnormalities, including circling, ataxia, head tilt, 
and bobbing (5,6). Histopathology reveals neuronal and axonal 
degeneration and gliosis (6). In three of four Mos transgenic 
lines displaying the severe neurological defect, greater than 
60% of the animals develop multicentric pheochromocytomas 
and/or medullary thyroid neoplasms after long latent periods. 
Moreover, the tumor histologies and patteras of presentation 
within these lines bear remarkable resemblance to those ob-
served in human MEN 2 (7-9). The tumor presentation pattem 
varies in a line-dependent manner and phenotype penetrance is 
background dependent. 
Materials and Methods 
Generation of transgenic lines 
Transgenic mice were generated as previously described 
(5,6). Murine Mos cDNA clones linked to the Moloney viras 
long terminal repeat (LTR) were microinjected into fertilized 
eggs from either FVB/N or B6C3F2 mice (10). 
Histopathology 
Formalin fixed tissues were embedded in paraffin, cut in five 
micron sections, and stained with hematoxylin and eosin. An 
improved immunoglobulin-bridge technique was used for the 
immunohistochemical staining (11). 
RNA expression analysis 
Total cellular RNA was prepared as described (12). In situ hy-
bridization analysis was carried out using S-^^ CTP on parafor-
maldehyde-fixed frozen sections. Sl hybridization was carried 
out as previously described (5,6). 
Results 
Histopathology 
Four of our Mos transgenic lines display aberrant lens-fiber 
differentiation as well as brain lesions consisting of neuronal 
and axonal degeneration and gliosis (5,6). Despite this, these an-
imals live for periods of longer than one year. Examination of 
tissues at 8 months of age reveals pheochromocytomas and/or 
medullary (C-cell) thyroid carcinomas in three of four of these 
Mos transgenic lines. Thus, we find that 58% of line 1 
transgenic Mos mice develop bilateral adrenal gland pheochro-
mocytomas (Table 1). Multifocal pheochromocytomas are ob-
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Table 1 
Tumor Incidence in Transgenic and Control Mice 
Percentage of Mice With Tumors 
Transgenic Number of Pheochromocytomas Medullary Thyroid 
Mouse Line Background Animals Only Neoplasia Only Both Total 
1 FVB/N 154 (79/75*) 58% (39/51) 0% (0/0) 4% (1/5) 62% (40/56) 
2 FVB/N 83 (39/44) 0% (0/0) 63% (19/33) 4% (0/3) 66% (19/36) 
3 FVB/N 89 (48/41) 2% ( l / I ) 0% (0/0) 0% (0/0) 2% (1/1) 
4 B6C3 62 (29/33) 23% (7/7) 13% (4/4) 32% (8/12) 68% (19/23) 
pLSM-1.2 B6C3 37(17/20) 0% (0/0) 0% (0/0) 0% (0/0) 0% (0/0) 
Control FVB/N 46 (21/25) 2% (I/O) 0% (0/0) 0% (0/0) 2% (1/0) 
* Actual number of males/females. 
•1 
Fig 1—Multiple pheochromocytomas within one adtenal (he-
matoxylin-eosin stain). 
served within one adrenal gland, or the entire gland can be re-
placed by tumor (Fig 1). Line 2 Mos transgenic mice di,splay a 
62% incidence of multifocal C-cell hyperplasia of the thyroid 
and frank medullary thyroid carcinoma (MTC) (Table 1). Like 
the pheochromocytomas of the line 1 animals, the thyroid le-
sions of the line 2 animals are multifocal and the tumors are bi-
lateral, indicating that they also arise in a polyclonal fashion 
(Fig 2). Line 4 Mos transgenic animals develop multifocal pheo-
chromocytomas as well as medullary thyroid neoplasms, with 
animals quite often having both types of tumors (Table 1). 
In contrast to lines 1,2, and 4 mice, the line 3 Mos transgenic 
mice fail to develop pheochromocytomas or C-cell thyroid neo-
plasms above the sporadic background level observed in the 
nontransgenic control animals (Table 1), even though their lens-
fiber development defect and neuropathology are indistinguish-
able from the other lines (5,6). 
RNA expression studies 
To demonstrate that the tumors observed in these animals 
were related to Mos expression, we examined the adrenal and 
thyroid tumors from line 4 Mos transgenic animals for Mos 
RNA expression by Northera analysis. We found that the adre-
nal and thyroid tumors, like the affected brains, express high 
levels of Mos RNA (13). The unaffected organs, like liver and 
kidney, however, are negative by Northem analysis, and the tis-
sues from nontransgenic control litter mates show little or no ex-
pression of Mos RNA (13). When the thyroid tumors are exam-
ined via in situ hybridization for mos expression, one sees high 
level expression of the transgene specifically over areas of tu-
mor involvement (Fig 3). 
To investigate whether c-mos is expressed in tissue derived 
from human MEN 2 tumors, we carried out S1 nuclease protec-
tion assays on both pheochromocytomas and MTCs. Of nine tu-
mors tested, only one showed low level mos expression. Fur-
thermore, no detectable expression of c-mos was found in the 
MZCRC, TT, and 6-23 cell lines, all of which were initially de-
rived from human C-cell thyroid cancers (data not shown). 
Immunohistochemistry 
In human pheochromocytomas, one observes high level ex-
pression of markers of neuroendocrine differentiation (11). The 
tumors in the transgenic Mos animals express some of the neu-
roendocrine markers that are detected in human tumors, such as 
neuron-specific enolase (NSE) (11). Pheochromocytomas from 
a line 1 mouse reveal a variable NSE nodular staining pattera, 
with lesions staining from intense to not detectable (Fig 4). The 
spontaneous pheochromocytoma from a normal FVB/N mouse 
as well as unaffected adrenal glands from line 2 and 3 mice show 
diffuse staining for NSE (data not shown). Calcitonin (CT) 
staining of thyroid tumors shows multiple nests of CT-positive 
cells with a staining pattem indistinguishable from that ob-
served in human tumors (13). 
It is mo.st common for MEN 2 patients to develop C-cell thy-
roid neoplasms as well as pheochromocytomas, the same pat-
tem of tumor development observed in the line 4 transgenic 
mice. Some kindreds, however, develop MTCs without devel-
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Fig 2—Medullary thryoid carcinoma (hemato.xylin-eosin stain). 
oping pheochromocytomas. This is a pattem observed in line 2 
mice. Since the clinical presentation of pheochromocytomas 
without MTC is rare in MEN 2, we examined the thyroids of line 
1 mice for the presence of C-cell hyperplasia, via CT staining. 
This indeed reveals the precursor lesion of MTC (13). 
Transgenic mice carrying a kinase deficient Mos 
In order to investigate the effect that the LTR promoter had on 
tissue specificity and on tumorigenesis, we generated two lines 
of transgenic mice (pLSM-1, pLSM-2 [Table 1]) that contained 
the identical transgene with the exception of a 350 bp deletion in 
the 5' region. This deletes the ATP binding domain and renders 
the protein produced kinase deficient. As can be seen in Table 1, 
no tumor formation was found. Additionally, when we exam-
ined tissues in these mouse lines for expression of the transgene 
via Northera hybridization analysis, we found high level expres-
sion in muscle and kidney and undetectable level in brain, adre-
nal, and thyroid (data not shown). 
Fig 3—In situ hybridization of medullary thyroid carcinoma. 
Dark-black grains represent signal fi-om S^^-labeled mos-probe. 
Effect of background on phenotype 
The tumor presentation pattera was line-dependent (Table 1) 
suggesting that the transgene integration site or the background 
of the animal played an important role. To evaluate this, the 
three Mos transgenic FVB/N lines were crossed with BALB/c 
mice (Table 2). The same disease phenotype was seen in the F, 
animals of the first two lines. The F, animals of the line 3 X 
BALB/c cross, however, display a high frequency of both pheo-
chromocytomas and medullary thyroid C-cell carcinomas even 
though neither neoplasm is found in the parental line. Thus, it is 
the integration site and/or background which affects the pene-
trance of the transgene on phenotype. 
Fig 4—Immunohistochemical staining of multiple pheochro-
mocytomas exhibiting variable staining with neuron-specific 
enolase. 
Of interest are preliminary results involving line 3 crosses to 
yet another background. When C3H mice are crossed to line 3 
transgenics, the phenotype observed is similar to that seen in hu-
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Table 2 
Tumor Incidence in Offspring of Transgenic Mice Crossed to BALB/c Mice 
Cross 
Number of 
Animals 
PheochromocytoiTias 
Only 
Percentage of Mice With Tumors 
Medullary Thyroid 
Neoplasia Only Both Total 
1 X BALB/c 49 (21/29*) 51% (12/13) 2% (0/1) 12% (1/5) 65% (13/19) 
2 X BALB/c 31 (16/15) 0% (0/0) 52% (7/9) 16% (1/4) 68% (8/13) 
3 X BALB/c 15(7/8) 7% (1/0) 33% (3/2) 20% (1/2) 60% (5/4) 
* Actual number of males/females. 
mans with the MEN 1 syndrome with a high incidence of pitu-
itary adenomas and pancreatic islet cell hyperplasia being seen 
(unpublished data). 
Discussion 
We have previously shown that extensive neuropathological 
changes such as gliosis and axonal degeneration are observed in 
mouse transgenic lines on two backgrounds harboring the LTR-
Mos allele (5,6). Here we show a high incidence of pheochro-
mocytomas and/or medullary thyroid neoplasms (62% to 68%) 
in three of the four Mos transgenic lines after approximately 8 
months of age. Although all lines display similar lens cell and 
neurological defects, the frequency and type of tumor vary (Ta-
ble 1). Thus, animals from lines 1 and 2 display either pheochro-
mocytomas or medullary thyroid neoplasms, respectively, with 
few animals developing both tumors. In contrast, the line 4 mice 
present either tumor type and often develop both pheochro-
mocytomas and thyroid C-cell carcinomas. 
The variation of tumor presentation pattern between the 
transgenic lines is similar to that observed in humans with MEN 
2. In the human syndrome, the tumor presentation pattera is con-
sistent within a kindred (11). The most commonly observed pat-
tem of tumor formation in humans with MEN 2 is the presence 
of both MTCs and pheochromocytomas, as we observe in the 
line 4 animals. Staining the thyroids of line 1 animals for CT re-
vealed evidence for C-cell hyperplasia, the precursor lesion of 
MTC. The study of these two lines could reveal mechanisms 
whereby there is preference given to the predisposition towards 
one tumor type or the other. For example, it is possible that the 
differences are due to the time that the transgene is expressed 
during development. A far less common form of MEN 2 is ex-
hibited by patients who present only MTCs. These patients 
never develop pheochromocytomas (14), which is similar to the 
presentation observed in the line 2 Mos transgenic animals. 
The differences in tumor presentation patteras in the various 
lines may be attributable to variations in the level of transgene 
expression or may reflect earlier activation of expression in the 
target organ of the tumor-bearing lines. This could be due to the 
transgene integration site (15-19) or the genetic background 
used. As illustrated in Table 2, the interaction of transgene with 
genetic background can influence the penetrance of the pheno-
type. The tumor phenotypes of the Fj progeny of the FVB/N 
Mos transgenic lines crossed with BALB/c may change because 
of alterations in transgene expression. Alteraatively, it may be 
that a second genetic event (as suggested by the long latent pe-
riod before disease is observed in these animals) may be sup-
pressed in line 3 or predisposed to in the F, progeny. These 
transgenic lines provide a valuable opportunity to study the ge-
netic and molecular basis of tumor induction and may help in 
elucidating the mechanism of tissue targeting in human syn-
dromes. 
MEN 2 has been assigned to chromosome 10 by linkage stud-
ies (20-22), while Mos is located on human chromosome 8 (23). 
However, the marked similarity between the pathologies of 
MEN 2 and the Mos transgenic mice suggests that the Mos-LTR 
transgene may function in the same pathway that gives rise to 
MEN 2. In that regard, we have examined nine tumors from 
MEN 2 patients and find only one positive for Mos expression 
(data not shown). C-mos transcripts were reported as being non-
detectable in a larger number of MEN 2 tumors by Moley et al 
(24). 
The c-Mos product has been identified as an essential compo-
nent of cytostatic factor (CSF) (25). an activity believed to be re-
sponsible for arresting mature oocytes at metaphase II and for 
stabilizing maturation-promoting factor (MPF). MPF is consid-
ered a universal regulator of meiosis and mitosis in eukaryotes 
(26-28). We have postulated that the transformed phenotype in-
duced by the Mos product may be due to the expression of M-
phase activities during interphase. Due to its downstream M-
phase function, Mos may be a proximal effector of the trans-
formed phenotype by comprising earlier signal transduction 
controls. Mos is expressed in adult (29-31) and embryonal brain 
(data not shown), and its constitutive expression in the 
transgenic animals in cells of neural crest origin may be respon-
sible for tumor formation in the adrenal medulla and thyroid 
(unpublished data, not shown). The long latent period for tumor 
formation in these mice suggests that there are multiple steps in 
neoplastic progression, perhaps some of which are related to the 
chromosomal loci associated with human MEN 2. 
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